Rhaeos, a clinical-stage medical device technology company, is in the process of developing an FDA-designated breakthrough technology designed to revolutionize the management of hydrocephalus. Hydrocephalus is a debilitating neurological condition that affects more than one million Americans. It is characterized by an abnormal accumulation of cerebrospinal fluid (CSF) in the brain's ventricles and often necessitates surgical intervention through the implantation of shunts to divert excess CSF away from the brain.
Rhaeos is addressing this critical issue with FlowSense, an innovative wearable and wireless CSF flow monitor, which is the first of its kind globally. This novel FlowSense shunt monitor offers a non-invasive, wireless, and thermal sensor solution, fulfilling an unmet clinical need for individuals suffering from hydrocephalus.
Furthermore, FlowSense's unique capability to collect data during sleep opens up new avenues for research into CSF flow dynamics, thereby enhancing our understanding of the pathophysiology of hydrocephalus.
The project has received prior funding to support the design and clinical testing of FlowSense within hospital settings through a multi-center clinical study. This study aims to enable rapid spot checks of CSF flow at the patient's bedside.
Source: prnewswire.com
